Abstract
Background Accurate population estimates of disease incidence and burden are needed to set appropriate public health policy. The capture-recapture (C-R) method combines data from multiple sources to better estimate prevalence than is possible using single sources. This study used the C-R method to estimate influenza cases using research and administrative databases to calculate county-wide influenza hospitalization burden.
Methods Data were derived from a database of clinical virology test results and research data from an influenza vaccine effectiveness study from seasons 2015-2016 to 2018-2019. Missed influenza cases were estimated using C-R method. These estimates were used to calculate disease burden using the multiplier method to correct for underreporting due to curtailing data collection before the end of influenza circulation.
Results Over all seasons, 422 influenza cases were reported in the administrative database and 382 influenza cases in the research database. Seventy-five cases (18%) reported in the administrative database were not captured in the research database, and 35 (9%) cases in the research database were not captured in the administrative database. Completeness of the influenza hospitalization was estimated to be 76%. Influenza hospitalizations were higher among unvaccinated (32%) than vaccinated (22%) in the current season and among unvaccinated (28%) than vaccinated (23%) in the previous year. The incidence rates for influenza hospitalizations varied by age and season and averaged 421 cases/100,000 population annually.
Conclusion The capture-recapture method offers a more accurate method for estimating influenza hospitalization than relying on a single data source. Using the multiplier method with adjustments improves the detection of influenza disease burden through a matched database. The incidence rates are consistent with national estimates.
Competing Interest Statement
Drs. Nowalk and Balasubramani, and Mr. Lyons have grant funding from Merck & Co., Inc. for an unrelated project. Dr. Zimmerman has grant funding from Sanofi Pasteur and Merck & Co., Inc. Dr. Silveira has grant funding from Shire, Ansun, Novartis for unrelated projects. Dr. Middleton reports personal fees from Seqirus, grants and personal fees from Pfizer, personal fees from Sanofi Pasteur. Dr. Yassin and Mr. Clarke have no conflicts to report.
Clinical Trial
This study was not registered with clinicaltrials.gov because it is a data analysis from an observational study.
Funding Statement
This work was supported by the Centers for Disease Control and Prevention (CDC) [5U01IP001035-02] and by National Institutes of Health (NIH) [UL1TR001857].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Pittsburgh IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by the Centers for Disease Control and Prevention (CDC) [5U01IP001035-02] and by National Institutes of Health (NIH) [UL1TR001857]. This work represents the views of the authors and not the CDC or NIH. It is subject to CDC’s public access policy.
Conflict of Interest: Drs. Nowalk and Balasubramani, and Mr. Lyons have grant funding from Merck & Co., Inc. for an unrelated project. Dr. Zimmerman has grant funding from Sanofi Pasteur and Merck & Co., Inc. Dr. Silveira has grant funding from Shire, Ansun, Novartis for unrelated projects. Dr. Middleton reports personal fees from Seqirus, grants and personal fees from Pfizer, personal fees from Sanofi Pasteur. Dr. Yassin and Mr. Clarke have no conflicts to report.
Data Availability
Data may be made available at the end of the cooperative agreement, with CDC's permission.